Three researchers share the prize for discovering channelrhodopsin, a light-sensitive protein now being tested to restore vision in retinal disease.
Commentary|Articles|September 15, 2026
A first for advanced RP: Bakall on the MOGENRY BLA acceptance and what an in-office option would mean
Author(s)Kassi Filkins, Benjamin Bakall, MD, PhD
Benjamin Bakall, MD, PhD, weighs the RESTORE efficacy and safety data, the practical realities of in-office delivery, and how genotype-independent treatment reshapes candidacy and patient counseling.
Advertisement
Advertisement
The US Food and Drug Administration (FDA) recently accepted Nanoscope Therapeutics’ biologics license application (BLA) for sonpiretigene isteparvovec (MOGENRY, formerly MCO-010), an investigational gene-agnostic optogenetic therapy for retinitis pigmentosa (RP) with severe vision loss.
Related to this article
Japan's filing covers IRDs broadly, supported by RESTORE and open-label Stargardt data.
4DMT's 4D-150 gene therapy enters phase 3 4SIGHT trial in DME; 2-year SPECTRA data show +10.8-letter BCVA gain in 9 patients.
Inherited metabolic diseases affect the retina even before the systemic diagnosis is established.
An industry symposium on intravitreal 4D-150 and a course on subretinal delivery lead gene therapy content at EURETINA 2026, alongside IRD courses and trial readouts.
Tarcocimab, tabirafusp-ted were noninferior to aflibercept in DAYBREAK wet AMD trial; 54% on tarcocimab reached 24-week dosing.
Real-world VOYAGER data at EURETINA 2026 show vision and anatomic outcomes with faricimab across nAMD, DME, and RVO.
Serena Salvatore, MD, discusses the retinal laser training gap, persistent laser myths, simulation and practical advice for safer laser at EURETINA 2026.
Advertisement
Advertisement